Soluble SIGLEC1 as a biomarker of disease activity in idiopathic inflammatory myopathies
Main finding · scSIGLEC1 level, active vs inactive disease on PGAResult — go to the resultDifference 2.7 ng/ml 95% CI 0.7–4.8Authors' conclusion
scSIGLEC1 levels are a promising biomarker for monitoring overall IIM disease activity, as well as activity involving the cutaneous, musculoskeletal and gastrointestinal systems.
Study context
- Population
- Canadian multicentre cohort of idiopathic inflammatory myopathies (IIM) patients with biobanked serum and clinical data at baseline and 1-year follow-up67.8% female
- Participants
- 87 participants
- Exposure
- scSIGLEC1 levels in active vs inactive disease; scSIGLEC1 vs MYOACT and creatine kinase for assessing disease activity
- Outcome
- Baseline serum scSIGLEC1 levels in relation to disease activity (PGA, TIS, MYOACT organ VAS)
- Follow-up
- Baseline
Methodological detailsmulticentre, biobanked serum samples
- Multicentre
- Biobanked serum samples
Main finding
As reported in the abstract
scSIGLEC1 level, active vs inactive disease on PGA
Difference
2.7 ng/ml
95% CI 0.7–4.8
Active diseasevs Inactive disease
difference 2.7 ng/ml (95% CI 0.7–4.8)
Observational data: associations, not effects.
Further findings
| Outcome | Values | Difference (ng/ml) (95% CI) | |
|---|---|---|---|
| scSIGLEC1 level, organ disease activity vs none (cutaneous, skeletal, gastrointestinal) · baselineCutaneous activityvs No cutaneous activity | 1.7 (0.1–3.4) | ||
| scSIGLEC1 level, organ disease activity vs none (cutaneous, skeletal, gastrointestinal) · baselineSkeletal activityvs No skeletal activity | 2.0 (0.1–3.9) | ||
| scSIGLEC1 level, organ disease activity vs none (cutaneous, skeletal, gastrointestinal) · baselineGastrointestinal activityvs No gastrointestinal activity | 2.2 (0.5–3.9) | ||
| −2024Difference, ng/ml (linear scale) |
| Outcome | Values |
|---|---|
| Performance in assessing disease activity | scSIGLEC1 AUC 0.74 (95% CI 0.61-0.86) |
Total Improvement Scores (TIS) at 1-year follow-up
- Higher scSIGLEC1 levels associated with lower TIS scores at 1-year follow-up
Performance in assessing disease activity
- scSIGLEC1 matched MYOACT performance and outperformed creatine kinase
Original publication
Soluble SIGLEC1 as a biomarker of disease activity in idiopathic inflammatory myopathies. Rheumatology (Oxford). Published 23 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →